Search

Your search keyword '"Karam, Irene"' showing total 383 results
Start Over Author "Karam, Irene"
383 results on '"Karam, Irene"'

2. Quality of life issues in patients with ductal carcinoma in situ: a systematic review

Author

Rajeswaran, Thenugaa, Gojsevic, Milena, Chan, Adrian Wai, Wong, Henry C. Y., Lee, Shing Fung, Bernard, Rhys, Marta, Gustavo Nader, Pogoda, Katarzyna, Kwan, Jennifer Y. Y., Kuszaj, Olivia, Day, Marley, Behroozian, Tara, Bleiker, Eveline M. A., Wong, Cindy, Kikawa, Yuichiro, Tane, Kaori, Velikova, Galina, Marcou, Yiola, Bjelic-Radisic, Vesna, Karam, Irene, Al-Khaifi, Muna, Kennedy, Samantha K. F., and Chow, Edward

Published
2024
Full Text
View/download PDF

4. StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a pilot study

Author

Kennedy, Samantha K. F., Gojsevic, Milena, Rajeswaran, Thenugaa, Zhang, Liying, Kuszaj, Olivia, Day, Marley, Karam, Irene, Vesprini, Danny, Leung, Eric, Szumacher, Ewa, Rakovitch, Eileen, Soliman, Hany, Chen, Hanbo, Lee, Shing Fung, Behroozian, Tara, Tran, William, Wronski, Matt, Gallant, Francois, Carothers, Katherine, Yewhans, Tiegsti, Wong, Cindy, Wong, Henry, and Chow, Edward

Published
2024
Full Text
View/download PDF

12. Patient-reported experience with the use of Mepitel Film for prevention of acute radiation dermatitis in breast cancer

Author

Gojsevic, Milena, Kennedy, Samantha, Rajeswaran, Thenugaa, Herst, Patries, Safavi, Amir H., Corbin, Kimberly, Hill, Rosemary, Tran, William, Carothers, Katherine, Gallant, François, Trombetta, Mark, Arscott, William T., Shariati, Saba, Lam, Jacqueline, Akkila, Shereen, Behroozian, Tara, Zhang, Elwyn, Karam, Irene, and Chow, Edward

Published
2024
Full Text
View/download PDF

13. Perceptions of healthcare professionals on the use of Mepitel Film for the prevention of acute radiation dermatitis in breast cancer

Author

Rajeswaran, Thenugaa, Kennedy, Samantha K. F., Gojsevic, Milena, Herst, Patries, Safavi, Amir H., Corbin, Kimberly, Hill, Rosemary, Karam, Irene, Tran, William, Gallant, François, Carothers, Katherine, Lam, Jacqueline, Trombetta, Mark, Arscott, William T., Shariati, Saba, Akkila, Shereen, Behroozian, Tara, Zhang, Elwyn, and Chow, Edward

Published
2023
Full Text
View/download PDF

16. Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial

Author

Moore-Palhares, Daniel, Dasgupta, Archya, Saifuddin, Murtuza, Anzola Pena, Maria Lourdes, Prasla, Shopnil, Ho, Ling, Lu, Lin, Kung, Joseph, McNabb, Evan, Sannachi, Lakshmanan, Vesprini, Danny, Chen, Hanbo, Karam, Irene, Soliman, Hany, Szumacher, Ewa, Chow, Edward, Gandhi, Sonal, Trudeau, Maureen, Curpen, Belinda, Stanisz, Greg J., Kolios, Michael, and Czarnota, Gregory J.

Subjects
Microbubbles -- Usage, Breast cancer -- Care and treatment, Radiotherapy -- Usage -- Quality management, Biological sciences
Abstract

Background Preclinical studies have demonstrated that tumour cell death can be enhanced 10- to 40-fold when radiotherapy is combined with focussed ultrasound-stimulated microbubble (FUS-MB) treatment. The acoustic exposure of microbubbles (intravascular gas microspheres) within the target volume causes bubble cavitation, which induces perturbation of tumour vasculature and activates endothelial cell apoptotic pathways responsible for the ablative effect of stereotactic body radiotherapy. Subsequent irradiation of a microbubble-sensitised tumour causes rapid increased tumour death. The study here presents the mature safety and efficacy outcomes of magnetic resonance (MR)-guided FUS-MB (MRgFUS-MB) treatment, a radioenhancement therapy for breast cancer. Methods and findings This prospective, single-center, single-arm Phase 1 clinical trial included patients with stages I-IV breast cancer with in situ tumours for whom breast or chest wall radiotherapy was deemed adequate by a multidisciplinary team (clinicaltrials.gov identifier: NCT04431674). Patients were excluded if they had contraindications for contrast-enhanced MR or microbubble administration. Patients underwent 2 to 3 MRgFUS-MB treatments throughout radiotherapy. An MR-coupled focussed ultrasound device operating at 800 kHz and 570 kPa peak negative pressure was used to sonicate intravenously administrated microbubbles within the MR-guided target volume. The primary outcome was acute toxicity per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Secondary outcomes were tumour response at 3 months and local control (LC). A total of 21 female patients presenting with 23 primary breast tumours were enrolled and allocated to intervention between August/2020 and November/2022. Three patients subsequently withdrew consent and, therefore, 18 patients with 20 tumours were included in the safety and LC analyses. Two patients died due to progressive metastatic disease before 3 months following treatment completion and were excluded from the tumour response analysis. The prescribed radiation doses were 20 Gy/5 fractions (40%, n = 8/20), 30 to 35 Gy/5 fractions (35%, n = 7/20), 30 to 40 Gy/10 fractions (15%, n = 3/20), and 66 Gy/33 fractions (10%, n = 2/20). The median follow-up was 9 months (range, 0.3 to 29). Radiation dermatitis was the most common acute toxicity (Grade 1 in 16/20, Grade 2 in 1/20, and Grade 3 in 2/20). One patient developed grade 1 allergic reaction possibly related to microbubbles administration. At 3 months, 18 tumours were evaluated for response: 9 exhibited complete response (50%, n = 9/18), 6 partial response (33%, n = 6/18), 2 stable disease (11%, n = 2/18), and 1 progressive disease (6%, n = 1/18). Further follow-up of responses indicated that the 6-, 12-, and 24-month LC rates were 94% (95% confidence interval [CI] [84%, 100%]), 88% (95% CI [75%, 100%]), and 76% (95% CI [54%, 100%]), respectively. The study's limitations include variable tumour sizes and dose fractionation regimens and the anticipated small sample size typical for a Phase 1 clinical trial. Conclusions MRgFUS-MB is an innovative radioenhancement therapy associated with a safe profile, potentially promising responses, and durable LC. These results warrant validation in Phase 2 clinical trials. Trial registration clinicaltrials.gov, identifier NCT04431674., Author(s): Daniel Moore-Palhares 1,2,3, Archya Dasgupta 1,2,3, Murtuza Saifuddin 3, Maria Lourdes Anzola Pena 3, Shopnil Prasla 3, Ling Ho 1, Lin Lu 1, Joseph Kung 1, Evan McNabb 3, [...]

Published
2024
Full Text
View/download PDF

18. Mepitel film for the prevention and treatment of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials

Author

Shariati, Saba, Behroozian, Tara, Kennedy, Samantha, Caini, Saverio, Herst, Patries M., Zhang, Liying, Ding, Keyue, Karam, Irene, van den Hurk, Corina, Wolf, Julie Ryan, Lee, Shing Fung, Wong, Henry, Chan, Adrian Wai, Ogita, Mami, Ye, Jason C., Chan, Raymond J., Gojsevic, Milena, Rajeswaran, Thenugaa, Bonomo, Pierluigi, and Chow, Edward

Published
2023
Full Text
View/download PDF

22. Nasopharyngeal Carcinoma

Author

Karam, Irene, Lee, Nancy Y., Le, Quynh-Thu, O’Sullivan, Brian, Lu, Jiade J., Poon, Ian, Lee, Nancy Y., Series Editor, Lu, Jiade J., Series Editor, and Yu, Yao, editor

Published
2022
Full Text
View/download PDF

26. Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study

Author

Cardenas, Carlos E., Blinde, Sanne E., Mohamed, Abdallah S.R., Ng, Sweet Ping, Raaijmakers, Cornelis, Philippens, Marielle, Kotte, Alexis, Al-Mamgani, Abrahim A., Karam, Irene, Thomson, David J., Robbins, Jared, Newbold, Kate, Fuller, Clifton D., and Terhaard, Chris

Published
2022
Full Text
View/download PDF

32. Quantitative US Delta Radiomics to Predict Radiation Response in Individuals with Head and Neck Squamous Cell Carcinoma

Author

Osapoetra, Laurentius Oscar, primary, Dasgupta, Archya, additional, DiCenzo, Daniel, additional, Fatima, Kashuf, additional, Quiaoit, Karina, additional, Saifuddin, Murtuza, additional, Karam, Irene, additional, Poon, Ian, additional, Husain, Zain, additional, Tran, William T., additional, Sannachi, Lakshmanan, additional, and Czarnota, Gregory J., additional

Published
2024
Full Text
View/download PDF

37. Lymph node yield: Impact on oncologic outcomes in oral cavity cancer.

Author

Khalil, Carlos, Khoury, Mark, Higgins, Kevin, Enepekides, Danny, Karam, Irene, Husain, Zain Ali, Bayley, Andrew, Poon, Ian, Truong, Tra, Chan, Kelvin K. W., Smoragiewicz, Martin, Fu, Rui, and Eskander, Antoine

Subjects
NECK dissection, LYMPH nodes, ORAL cancer, PROPORTIONAL hazards models, SQUAMOUS cell carcinoma, LYMPHATIC metastasis
Abstract

Background: Lymph node metastases are associated with poor prognosis in oral cavity squamous cell carcinoma (OCSCC). In other cancers, clinical guidelines on the number of lymph nodes removed during primary surgery, lymph node yield (LNY), exist. Here, we evaluated the prognostic capacity of LNY on regional failure, locoregional recurrence, and disease‐free survival (DFS) in patients with OCSCC treated by primary neck surgery. Methods: This retrospective cohort study took place at Sunnybrook Health Sciences Centre in Toronto, Canada and involved a chart review of all adult patients with treatment‐naive OCSCC undergoing primary neck dissection. For each outcome, we first used the maximally selected rank statistics and an optimism‐corrected concordance to identify an optimal threshold of LNY. We then used a multivariable Cox proportional hazards model to assess the association between high LNY (>threshold) and each outcome. Results: Among the 579 patients with OCSCC receiving primary neck dissection, 61.7% (n = 357) were male with a mean age of 62.9 years (standard deviation: 13.1) at cancer diagnosis. When adjusting for sociodemographic and clinical factors, LNY >15 was significantly associated with improved DFS (adjusted HR [aHR]: 0.73, 95% CI: 0.54–0.98), locoregional recurrence (aHR: 0.68, 95% CI: 0.49–0.95), and regional failure (aHR: 0.61, 95% CI: 0.39–0.93). Conclusions: Our study findings suggested high LNY to be a strong independent predictor of various patient‐level quality of surgical care metrics. The optimal LNY we found (15) was lower than the conventionally recommended (18), which calls for further research to establish validity in practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Interventions for Concerning Patient-Reported Outcomes in Routine Cancer Care: A Systematic Review

Author

Sampieri, Gianluca, primary, Li, Huaqi, additional, Ataalla, Philopateer, additional, Merriman, Kaitlyn, additional, Noel, Christopher W., additional, Hallet, Julie, additional, Coburn, Natalie, additional, Karam, Irene, additional, Smoragiewicz, Martin, additional, Wong, Brian, additional, Fu, Rui, additional, and Eskander, Antoine, additional

Published
2023
Full Text
View/download PDF

48. Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative

Author

Malik, Nauman H., primary, Fu, Rui, additional, Hainc, Nicolin, additional, Noel, Christopher W., additional, de Almeida, John R., additional, Hosni, Ali, additional, Huang, Shao Hui, additional, Yu, Eugene, additional, Dzioba, Agnieszka, additional, Leung, Andrew, additional, Mangat, Arvindpaul, additional, MacNeil, Danielle, additional, Nichols, Anthony C., additional, Hiremath, Shivaprakash B., additional, Chakraborty, Santanu, additional, Jooya, Alborz, additional, Gaudet, Marc, additional, Johnson‐Obaseki, Stephanie, additional, Whelan, Jonathan, additional, Forghani, Reza, additional, Hier, Michael P., additional, Morand, Grégoire, additional, Sultanem, Khalil, additional, Dort, Joseph, additional, Lysack, John, additional, Matthews, Wayne, additional, Nakoneshny, Steven, additional, Gill, Gia, additional, Globerman, Adam, additional, Kerr, Paul, additional, Maralani, Pejman, additional, Karam, Irene, additional, and Eskander, Antoine, additional

Published
2023
Full Text
View/download PDF

50. COVID-19 pandemic impact on the potential exacerbation of screening mammography disparities: a population-based study in Ontario, Canada

Author

Fu, Rui, primary, Tinmouth, Jill, additional, Li, Qing, additional, Dare, Anna, additional, Hallet, Julie, additional, Coburn, Natalie, additional, Lapointe-Shaw, Lauren, additional, Look Hong, Nicole J., additional, Karam, Irene, additional, Rabeneck, Linda, additional, Krzyzanowska, Monika, additional, Sutradhar, Rinku, additional, and Eskander, Antoine, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results